Sage Therapeutics (SAGE) said, “Based upon Sage’s current estimates, Sage expects that its current cash, cash equivalents and marketable securities, along with anticipated funding from ongoing collaborations and potential revenue, will support its operations into 2025. Additionally, Sage is evaluating resource allocation, including pipeline prioritization and a workforce reorganization, with a goal of extending its cash runway and anticipates operating expenses will decrease in 2024. We have the potential to earn a milestone payment of $75.0M from Biogen (BIIB) related to the first commercial sale of ZURZUVAE for the treatment of PPD.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAGE:
- Sage (NASDAQ:SAGE) Plummets On FDA Snub for Zuranolone in Major Depression Disorder
- Sage Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- Sage Therapeutics downgraded to Perform from Outperform at Oppenheimer
- Sage, Biogen receive CRL for zuranolone in major depressive disorder
- SAGE Upcoming Earnings Report: What to Expect?